Your browser doesn't support javascript.
loading
Real-World Evidence to Evaluate the Efficacy and Safety of Vonoprazan in Gastrointestinal Disorders in the Pakistani Population.
Abbasi, Amanullah; Siddiqui, Shajee Ahmad; Ram, Bikha; Khan, Jibran Umar Ayub; Sheikh, Khalid; Ali, Asif; Raja Memon, Waseem; Rehan, Muhammad; Zia Ul Haq, Muhammad; Kumar Seetlani, Naresh; Akhter, Tayyab S; Khoso, Masood; Javed, Asif; Hussain Khokhar, Riaz; Hussain Memon, Zaheer; Akbar, Wajid; Naeem, M; Shaikh, Samiullah; Khan Khattak, Abbas; Memon, A Qayoom; Bhatty, Shaheen; Sultan, Omar; Shani, Idress; Maheshwary, Neeta.
Affiliation
  • Abbasi A; Internal Medicine, Civil Hospital Karachi, Karachi, PAK.
  • Siddiqui SA; Internal Medicine, Pakistan Institute of Medical Sciences, Islamabad, PAK.
  • Ram B; Internal Medicine, Liaquat University of Medical and Health Sciences, Hyderabad, PAK.
  • Khan JUA; Internal Medicine, Kabir Medical College, Peshawar, PAK.
  • Sheikh K; Internal Medicine, People's University of Medical and Health Sciences for Women, Nawabshah, PAK.
  • Ali A; Internal Medicine, Civil Hospital Karachi, Karachi, PAK.
  • Raja Memon W; Medicine, Dow General Hospital/Dow University of Health Sciences, Karachi, PAK.
  • Rehan M; Medicine, People's University of Medical and Health Sciences for Women, Nawabshah, PAK.
  • Zia Ul Haq M; Medicine, Civil Hospital Karachi, Karachi, PAK.
  • Kumar Seetlani N; Medicine, Sir Ganga Ram Hospital, Lahore, PAK.
  • Akhter TS; Internal Medicine, Civil Hospital Karachi, Karachi, PAK.
  • Khoso M; Gastroenterology, Holy Family Hospital, Islamabad, PAK.
  • Javed A; Gastroenterology, Jinnah Postgraduate Medical Center, Karachi, PAK.
  • Hussain Khokhar R; Internal Medicine, Social Security New Born & Children Hospital (MNCH), Faisalabad, PAK.
  • Hussain Memon Z; Internal Medicine, People's University of Medical and Health Sciences for Women, Nawabshah, PAK.
  • Akbar W; Internal Medicine, Suleman Roshan Medical College, Tandoadam, PAK.
  • Naeem M; Internal Medicine, Bacha Khan Medical College, Peshawar, PAK.
  • Shaikh S; Gastroenterology, Mardan Medical Complex, Peshawar, PAK.
  • Khan Khattak A; Internal Medicine, Gijal Mao M/c Qasimabad, Hyderabad, PAK.
  • Memon AQ; Gastroenterology, Abyseen Plaza Dabgari, Peshawar, PAK.
  • Bhatty S; Gastroenterology, Private Clinic, Nawabshah, PAK.
  • Sultan O; Internal Medicine, Dr. Ruth K. M. Pfau Civil Hospital, Karachi, PAK.
  • Shani I; Internal Medicine, Jinnah Postgraduate Medical Center, Karachi, PAK.
  • Maheshwary N; Internal Medicine, District Head Quarters (DHQ) Hospital, Faisalabad, PAK.
Cureus ; 15(11): e48994, 2023 Nov.
Article in En | MEDLINE | ID: mdl-38111444
ABSTRACT
BACKGROUND AND

AIM:

While proton pump inhibitor (PPI) therapy has proven to be effective in managing gastroesophageal reflux disease (GERD), a notable portion of patients who experience GERD symptoms may not respond to this treatment. Research suggests that roughly 30% of individuals with a presumed GERD diagnosis may continue to experience symptoms, whether partially or completely, even when receiving PPI therapy. The aim of this study was to assess the treatment of gastrointestinal diseases with a novel potassium-competitive acid blocker (P-CAB), vonoprazan, in terms of its effectiveness and safety in the Pakistani population.

METHODS:

This prospective, multicenter, observational study was conducted in Pakistan. This study included 1,642 patients from January 2023 to August 2023, aged 18 years, with gastrointestinal disorders. All demographic data, medical history, GERD severity assessment questionnaire (GerdQ), and laboratory parameters, including stool assessment for Helicobacter pylori (H. pylori), were observed. Patients were orally treated with vonoprazan at doses of 10 mg or 20 mg, once or twice daily. Statistical analysis was done by one-way ANOVA.

RESULTS:

Out of 1,642 patients, 840 (51.2%) were males and 802 (48.8%) were females, with a mean age of 39.81±14.61 years. The mean GerdQ score at baseline was 20.37±15.87, 7.24±8.15 at the second week of treatment, and 3.70±6.31 at the fourth week of treatment (p<0.001). 90.74% of patients achieved H. pylori eradication. Most patients were acid regurgitation and heartburn-free for >70% of days. Most of the patients, 1,283 (78.13%), exhibited good treatment compliance. Mild adverse events were reported in 37 (2.3%) patients.

CONCLUSIONS:

The use of vonoprazan significantly reduced the likelihood of GERD by improving symptoms and was also highly effective in the elimination of H. pylori infections. Vonoprazan was generally well tolerated.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Cureus Year: 2023 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Cureus Year: 2023 Document type: Article